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Objectives: Ranibizumab and dexamethasone intravitrael(DEX) implant are 
authorised treatments for treatment of DME in Turkey. The objective of this study 
is to assess the cost-effectiveness of ranibizumab vs. dexamethasone implants in 
DME treatment with public payer’s perspective. MethOds: Two studies are used 
for indirect comparison to calculate the relative efficacy of ranibizumab vs. DEX 
implant over 12 months with endpoints of BVCA gains:(i)RESTORE comparing ranibi-
zumab vs. laser BVCA gains at month 12 (ii)MEAD comparing DEX implant vs sham 
injections BVCA gains at month 36. For months 12 to 36, the efficacy inputs are 
calibrated such that the trajectories of mean BCVA for the two comparators reflect 
those reported in RESTORE(extension) and MEAD respectively. Conservative transi-
tions probabilities were imposed on the ranibizumab arm, such that mean BCVA 
sustains the~8 letters gain but no further gain is assumed. These efficacy inputs 
are then validated by the MAGGIORE head to head study of ranibizumab and DEX 
implant. MAGGIORE couldn’t be used as a primary source of efficacy as the %gains 
of 10(or15 letters) were not reported. Units of resource use and withdrawal rates 
are obtained from RESTORE and MEAD. Mean number of yearly injection frequency 
for ranibizumab was 7.0, 3.9, 2.9 for year 1, year 2 and year 3 respectively;while for 
DEX implant yearly injection frequency was 2.4 for all three years. Unit costs of 
resources were obtained by using national fees per service lists and discounted by 
3.5% Results: Mean BCVA change from baseline at year 3 with ranibizumab arm 
was 7.2 and with DEX implant arm was 2.5 points. Incremental cost of gaining an 
extra year without visual impairment by treating with ranibizumab rather than DEX 
implant is 11.339TL. cOnclusiOns: Although conservative approach was pursued 
both in terms of efficacy for ranibizumab arm, incremental cost of gaining an extra 
year without visual impairment by treating with ranibizumab was negligible.
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Objectives: To estimate the cost-effectiveness of secukinumab ( Cosentyx®) com-
pared with ustekinumab (Stelara®) in patients with moderate to severe plaque pso-
riasis from a Swedish societal perspective. MethOds: A cost-minimization analysis 
was conducted to estimate the total treatment costs (including drug acquisition, 
monitoring and indirect costs) of secukinumab versus ustekinumab over periods up to 
ten years. Indirect costs were measured by estimated work productivity loss in three 
improvement categories incl. PASI < 50, PASI 50-74, PASI> 75. Data on PASI responses 
were based on head-to-head trial (CLEAR). Primary outcomes were total treatment 
costs over a time horizon of 1-10 years, and total costs per patient achieving PASI75 
and PASI90 (achieving clear or almost skin). Sensitivity analysis was performed to test 
the robustness of the model. Results: Secukinumab had higher treatment initia-
tion costs, but lower maintenance costs than ustekinumab. From year 2 onwards, 
secukinumab was cost-saving compared to ustekinumab. Total treatment costs after 
2 years were 338’022SEK and 339’550SEK for secukinumab and ustekinumab respec-
tively, resulting in savings of 1’529SEK. Extending the time period to 10 years resulted 
in savings of 50’460SEK. Based on the CLEAR study, a significantly higher propor-
tion of patients reached PASI75 and PASI90 with secukinumab vs ustekinumab (93% 
and 83% PASI75; 79% v 58% PASI90). Considering a 2-year time horizon, the average 
total cost per patient reaching PASI75 was 363’020SEK for secukinumab compared 
to 410’647SEK for ustekinumab. Corresponding numbers for PASI90 were 427’648SEK 
and 589’375SEK. Univariate sensitivity analyses showed that base-case Resultswere 
robust. cOnclusiOns: From a Swedish societal perspective, secukinumab was 
estimated to be cost-saving compared with ustekinumab. In addition to the lower 
total costs from year two onwards secukinumab has shown superior efficacy on PASI 
improvement and quality of life for patients, and can therefore be considered as the 
dominant treatment compared to ustekinumab.
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Objectives: Oral Isotretinoin (OI) is the gold standard for treating severe nodular 
acne but is associated with a significant adverse events burden. In the 20-week POWER 
trial, Adapalene 0.1% / Benzoyl Peroxide 2.5% (A/BPO), a topical fixed-dose combina-
tion treatment, plus oral antibiotic doxycycline 200mg/day (D+A/BPO) demonstrated 
a favourable composite efficacy/safety profile compared to OI in severe nodular acne 
patients. The objective of the present study was to assess the one-year cost-effec-
tiveness of D+A/BPO versus OI. MethOds: A Markov model was developed for the 
Swedish setting based on clinical effectiveness data from the POWER trial and the 
typical treatment pathway patients experience following treatment failure, discon-
tinuation or relapse. Patients’ acne was classified as “controlled” following at least 
2-grade improvement in the Investigator’s Global Assessment. Health state utility 
values (HSUV) for controlled and uncontrolled acne were estimated by applying the 
Swedish tariff to the EuroQOL five dimensions questionnaire responses collected 
at baseline and study end, although the difference in the two HSUVs was minimal. 
Adverse events observed in the POWER study were included, with impact on costs 
and quality of life. Results: D+A/BPO treatment was less costly than OI at 17,033 SEK 
versus 21,185 SEK per patient. Costs Resultsfavoured D+A/BPO due to the lack of costs 
associated with monitoring when receiving OI as well as lower adverse events treat-
ment costs, combined with lower frequency and cost of physician visits as patients 
treated with D+A/BPO consult a general practitioner rather than a dermatologist. The 
total number of Quality-Adjusted Life Years accrued over one year was comparable at 
0.9250 for D+A/BPO and 0.9318 for OI. Sensitivity analyses showed that D+A/BPO was 
no longer less costly when increasing the associated frequency of physician visits or 
decreasing visits with OI. cOnclusiOns: For severe nodular acne patients, D+A/BPO 
may be considered an attractive, lower-cost, first-line alternative to OI.
sis was conducted based on administrative databases from 2 Italian local health 
units (LHUs), ≈1.6 million beneficiaries. Citizens who were diagnosed with PsA or 
psoriasis and had a biologic prescription from January 1, 2010, to December 31, 2013 
(index date) were included. Patients were classified as biologic-naïve or biologic-
established according to previous biologic treatment, and analysed 1 year back 
to assess resource consumption in the 2 groups. Results: According to findings 
from the 2 LHUs, 86% of biologic-naive patients had previous disease-modifying 
anti-rheumatic drug (DMARD) prescriptions and 47% had previous topical anti-
psoriatic prescriptions. Exposure to DMARDs and anti-psoriatic drugs was lower 
in biologic-established patients (43% and 33%, respectively). Yearly incidence of 
disease-related hospitalisations before the index date was 7% in biologic-naive 
and 13% in biologic-established patients. Biologic-naïve patients had longer aver-
age hospital lengths of stay. The average cost of illness in the 12 months before the 
first biologic prescription (biologic-naïve) was ≈760€ , with 530€ for DMARDs, 130€ 
for anti-psoriatics, and 101€ for inpatient stays. Non-PsA/psoriasis-related costs 
were 790€ , of which 57% were due to hospitalisations. Biologic-established patients’ 
yearly expenditure accounted for 10,410€ for biologic treatment, 265€ for other PsA/
psoriasis drugs (168€ DMARDs, 70€ anti-psoriatics, 26€ corticosteroids), and 410€ 
for hospitalisations. Non-disease-related expenditure was 630€ , with > 80% due to 
drug consumption. cOnclusiOns: At the index date, consumption of DMARDs and 
other anti-psoriatics was lower in biologic-established than biologic-naïve patients 
(43% vs 86% and 33% vs 47%, respectively), but overall drug expenditure was higher 
due to biologic acquisition cost (10,410€ vs 760€ ). Disease-related hospitalisations 
were higher in biologic-established patients treated the year before the index date 
(13% vs 7% of biologic-naïve patients).
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Objectives: Caries is the most common dental disease in industrial countries. 
Health expenditures for the treatment of caries were estimated 8.2 billion € in 2012 
in Germany. In order to prevent or at least delay progression, many prevention 
measures have been implemented at different levels. Consumption of sugar free 
gum (SFG) is one preventive measure at the individual level. The benefit of SFG in 
caries prevention is proven by numerous studies. The presented study evaluates the 
cost - effectiveness of SFG from the perspective of the patient based on copayment 
in Germany. MethOds: The development of the current status in dental health care 
is projected on a time horizon of 62 years. This is compared to a scenario where the 
consumption of SFG is increased to the Finnish level of consumption. Every tooth 
can range between the stages “No caries”, “1-4 area filling”, “Partial crown”, “Crown” 
and “Bridge / Prosthesis / Implant”. Transition probabilities were calculated based 
on the epidemiological data in the DMS IV. The calculation was conducted from the 
patients´ point of view including costs for copayment. Results: An increase in SFG 
consumption to a Finnish level leads to lifetime costs for caries of 16.882,73 € per 
patient for copayment. If the SFG consumption stays at its current level, the costs 
per patient are 23.801,11 € . As a result, in Germany an increase in SFG consumption 
leads to cost savings of about 7,000 € per patient within 62 years, or annual savings 
of 111 € . cOnclusiOns: Increasing the consumption of SFG leads to both improve-
ment of oral health and cost savings for the patient.
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Objectives: Actinic keratosis (AK) caused by chronic exposure to ultraviolet radi-
ation, is the most common premalignant dermatological disease in adults over 
60. Topical field treatments are effective in clinical and subclinical lesions. There 
are currently three topical treatment options available in Greece: diclofenac gel 
(3%), imiquimod (5%) and a recently launched agent: Ingenol mebutate gel (IM). 
The objective of the present study was to perform a cost-effectiveness analysis of 
IM vs other topical alternatives for the treatment of AK from a Greek healthcare 
perspective. MethOds: The analysis was conducted via a decision tree in order to 
calculate the clinical effects and associated costs of AK first-line treatments: IM (2-3 
days), diclofenac (3% for 8 or 12 weeks) and imiquimod (5% for 4 or 8 weeks), over a 
24-month horizon, divided in 6-month cycles, by considering a hypothetical cohort 
of immunocompetent adult patients with clinically confirmed AK on the face/scalp 
or trunk/extremities. Clinical data on the relative efficacy of the different strategies 
under consideration were obtained from a network meta-analysis, while inputs con-
cerning resource use, reflecting the clinical practice derived from an expert panel. 
All costs were calculated from a Greek third-party payer perspective. Results: 
IM 0.015% and 0.05% were both cost-effective compared to diclofenac and below a 
willingness- to-pay threshold of 30,000€ /QALY (7.857, and 4.451 € /QALY gained for IM 
0.015% compared to diclofenac 2xdaily for 8 and 12 weeks respectively). Comparing 
IM on face/scalp AK lesions for 3 days versus imiquimod (4 or 8 weeks) resulted in 
equivalent Results(22.964€ and 787€ /QALY gained) while IM use on trunk/extremi-
ties was dominant compared to imiquimod four weeks treatment. cOnclusiOns: 
From a social insurance perspective in Greece, IM 0.015% and IM 0.05% could be 
the most cost-effective first-line topical filed treatment options in all cases for the 
treatment of Actinic Keratosis.
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tions (i.e. PIER trial). The model assumes that patients discontinue treatment after the 
second year of treatment. Costs related to drug acquisition, administration, monitor-
ing costs and blindness were considered in the analysis (2015). This model predicted: 
blind-years, quality-adjusted life-years (QALYs), and the direct costs from a payer 
perspective. Results: Treatment without delay was found to be more beneficial 
compared to “with delay” treatment in terms of QALYs (4,487 vs. 4,190) and blind-years 
(1,084 vs. 1,511). The total lifetime cost was calculated to be € 235 higher in patients 
treated without any delay, resulting in an ICER of € 790 per QALY gained (well-below 
the threshold of € 17,000). The higher drug acquisition cost observed in “without delay” 
arm was partially offset by the increased non-medical direct cost related to the “with 
delay” arm. cOnclusiOns: Ranibizumab treatment of wAMD without delay seems 
to be a strongly cost-effective strategy in Greece.
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Objectives: Chronic spontaneous urticaria (CSU) is characterised by rapid appear-
ance of wheals, angioedema or both, with no obvious cause and with symptoms 
lasting for more than six weeks; CSU has a demonstrable negative impact on patient 
quality of life and societal productivity. The objective of this study was to assess 
the cost-utility of omalizumab compared with continued standard of care (SOC) 
for the treatment of patients with moderate or severe CSU with an inadequate 
response to SOC, from the UK societal perspective. MethOds: A Markov model 
was developed, defined by five disease severity health states and three additional 
states for relapse, spontaneous remission and death. The model considered 6 month 
courses of omalizumab treatment, with re-treatment upon relapse (relapse defini-
tion: UAS7≥ 16) and early discontinuation of non-responders (definition of response: 
UAS7≤ 6). Clinical and cost inputs were derived from omalizumab trials and pub-
lished sources; productivity inputs were informed by a non-interventional study 
and average earnings data. The base case considered a 20-year time horizon, and 
cost-utility was expressed as an incremental cost-effectiveness ratio (ICER). Scenario 
analyses included no early discontinuation of non-responders and an altered 
definition of response (UAS7< 16). Results: In the base case analysis, the deter-
ministic ICER was £3,183, with omalizumab being associated with increased costs 
and increased benefit relative to SOC. Probabilistic sensitivity analysis supported 
this result. Individual scenarios without early discontinuation of non-responders 
and adjusting the definition of response had little impact on Results(ICERs £4,409 
and £5,304, respectively). Further sensitivity analyses demonstrated robustness of 
Resultsto changes in key model parameters and inputs. cOnclusiOns: To our 
knowledge, this is the first economic evaluation of omalizumab in CSU from a UK 
societal perspective. Omalizumab was associated with consistently low ICERs across 
a range of different scenarios, demonstrating omalizumab to represent a treatment 
option with societal benefit for CSU in the UK.
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Objectives: Chronic spontaneous urticaria (CSU) is a skin disease, with itchy hives 
that last for at least 6 weeks without an obvious external trigger. Omalizumab has 
been shown to diminish clinical symptoms and signs. The objective of this study 
was to determine the cost-effectiveness of omalizumab relative to cyclosporine 
and standard of care (up to 4 times the daily dose of H1-antihistaminics) for the 
Netherlands. MethOds: A Markov model was used in this study. The model’s set-
tings and characteristics of the Dutch patient population were based on an online 
survey among clinical experts. These values were validated during a clinical expert 
committee meeting. The GLACIAL trial was used to describe transition probabilities. 
Data on health care consumption, quality of life and productivity losses were derived 
from medical records and a survey among 93 Dutch CSU patients. Health care con-
sumption was valued using prices from the Dutch costing manual. Utilities were 
derived from EQ-5D and calculated using Dutch tariffs. Productivity losses were val-
ued using Dutch wage rates. Comparator treatments were cyclosporine and standard 
of care. Uncertainty was assessed by one-way sensitivity analyses and probabilistic 
sensitivity analyses. Results: Omalizumab was more effective than cyclosporine 
(incremental QALYs: 11.3). Incremental costs for omalizumab were € 51.052, result-
ing in an ICER of € 4.510 per QALY gained. Compared to standard of care, incremental 
QALYs for omalizumab were 9.2 and incremental costs were € 161.342 (ICER of € 17.502/
QALY gained). Productivity costs played an important role in the value of the ICER. 
Probabilistic sensitivity analyses resembled the Resultsfrom the deterministic analy-
ses. cOnclusiOns: Omalizumab is cost-effective compared to both cyclosporine and 
standard of care. The ICER is well below the implicit cost-effectiveness threshold in 
the Netherlands, which ranges from € 20.000-80.000 per QALY.
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Objectives: To conduct a cost-utility analysis of ranibizumab versus aflibercept for 
the treatment of patients with visual impairment due to diabetic macular edema 
(DME) in the Greek setting. MethOds: A Markov model was adapted to compare the 
use of ranibizumab 0.5mg (pro re nata-PRN and treat & extend-T&E) to aflibercept 
2mg (every 8 weeks after 5 initial doses) in DME. Patients transitioned at a 3-month 
cycle among nine specified health states (including death) over a lifetime horizon. 
Transition probabilities, utilities as well as DME-related mortality incorporated in 
the model were extracted from relative clinical trials, a network meta-analysis and 
other published studies. The drug acquisition and administration costs as well as 
the costs of blindness and laser surgery were also incorporated in the analysis. The 
analysis was conducted from payer perspective and as such only costs reimbursed 
by the payer were considered (year 2014). Treatment costs and health outcomes 
were discounted by 3.5% annually. The incremental cost per quality-adjusted life 
year (QALY) gained and the net monetary benefit was the main outcome measures. 
Sensitivity analysis was conducted to test robustness of the model. Results: Τhe 
use of PRN and T&E ranibizumab regimens were shown to be cost saving compar-
ing to aflibercept by € 2,824 and € 22, respectively, and more beneficial in terms of 
QALYs gained (+0.05) and time without visual impairment (0.031 and 0.034 years), 
thereby dominating aflibercept. Moreover, ranibizumab used as PRN or T&E resulted 
in a net monetary benefit of € 3,984 and € 1,278, respectively. Sensitivity analysis 
revealed that the net monetary benefit for each regimen remained positive for all 
tested scenarios. cOnclusiOns: Both PRN and T&E ranibizumab regimens were 
more beneficial and less costly compared to aflibercept for the management of 
DME. Hence, ranibizumab seems to be a dominant option for the treatment of visual 
impairment due to DME in the Greek setting.
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Objectives: To estimate the incremental cost utility ratio (ICUR) for ingenol mebu-
tate vs imiquimod 5% for actinic keratosis (AK) patient’s treatment on the face 
and scalp, in Spain. MethOds: A Markov model was used to simulate AK patient 
treatment evolution for a 5-year horizon from the Spanish National Health System 
(NHS). Duration of ingenol mebutate treatments was 3 days and 12 days for imiqui-
mod 5%. Effectiveness measure was total clearance rate obtained from indirect 
mixed comparisons (42.24% for ingenol mebutate and 44.54% for imiquimod) and 
adjusted according compliance (90% for ingenol mebutate and 60% for imiquimod). 
Annual recurrence rate (20%) derived from literature. Annual discount rate of 3% 
was applied for costs and outcomes. Total cost estimation (€ ,2015) included: drug 
(retail price VAT included with mandatory deduction), and dermatology visits cost 
(for adverse events and disease management).Utilities values (0.986 for AK and 1 
for clearance) were used to derive quality-adjusted-life years (QALY). Probabilistic 
and deterministic sensitivity analyses were performed to confirm the robustness of 
the obtained results. Results: Ingenol mebutate showed higher effectiveness than 
imiquimod 5%, 0.535 vs 0.503 total gained clearances and 4.451 vs 4.449 total QALYs 
and accounted higher total costs, € 551.50 (46% drug cost) versus € 527.89 (36% drug 
cost) compared to imiquimod 5%. Estimated ICUR was € 10.906/QALY gained with 
ingenol mebutate vs imiquimod 5%. In probabilistic sensitivity analysis performed, 
78% of simulations yielded an ICUR below € 30,000/QALY for ingenol mebutate versus 
imiquimod. cOnclusiOns: Ingenol mebutato vs imiquimod 5% was an efficient 
alternative for NHS for patients with AK, on face and scalp, considering an accept-
able threshold of € 30,000/QALY.
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Objectives: To examine the impact of delay between indication to treat and injection 
of ranibizumab for the management of age-related macular degeneration (wAMD), in 
Greece. MethOds: A Markov model was developed to estimate, in a lifetime horizon, 
the clinical and cost outcomes related to treatment with ranibizumab 0.5mg on a 
pro re nata protocol: a) “without delay” and b) “with delay” between medical indica-
tion and treatment administration. At monthly cycles, patients’ visual acuity could 
increase by 3 lines, remain the same, or decrease by 3 lines. As for the “without delay” 
arm, the number of injections and transition probabilities were obtained from the 
CATT trial, while for the “with delay” arm, a one-month delay at first treatment was 
assumed, based on local experts estimation, and then the delay at re-treatment was 
indirectly modeled by applying number of injections and transition probabilities as 
obtained from clinical trials evaluating the efficacy of a quarterly protocol of injec-
